RASi plus carvedilol

ApprovedSmall molecule

FFederal University of Minas Gerais

RASi plus carvedilol is one of 4 small molecule programs targeting Chagas cardiomyopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chagas CardiomyopathyActive, not recruiting

Chagas CardiomyopathyApproved

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Chagas Cardiomyopathy

#DrugCompanyPhaseTrials

Zebeta

Teva

Phase 3

1 2

Neupogen

EEastern Cooperative Oncology Group

Phase 3

—3

RASi plus carvedilol

FFederal University of Minas Gerais

Approved

1 4

Amiodarone Hydrochloride

UUniversity of Calgary

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chagas cardiomyopathy1 trial

A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy

Completed·FFederal University of Minas Gerais·Phase 4·NCT01557140·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RASi plus carvedilol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RASi plus carvedilol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RASi plus carvedilol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal University of Minas Gerais company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FFederal University of Minas Gerais

RASi plus carvedilol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chagas cardiomyopathy1 trial

References

Drug Info

Quick Facts

Related News